Targeting C-reactive protein for the treatment of cardiovascular disease
Mark B. Pepys(University College London), Stephen P. Wood(University of Southampton), Gillian A. Gray(The Queen's Medical Research Institute), Martin D. Smith(University of Oxford), Alexander J. A. Cobb(The Royal Free Hospital), Darren A. Thompson(University of Sussex), Gideon M. Hirschfield(University Health Network), J. Andrew Aquilina(University of Wollongong), Philip N. Hawkins(The Royal Free Hospital), Steven V. Ley(University of Cambridge), Michelle C. Jenvey(University of Southampton), Alessandra Polara(University of Cambridge), R. M. Myers(University of Cambridge), Glenys A. Tennent(The Royal Free Hospital), J. Ruth Gallimore(The Royal Free Hospital), Vittorio Bellotti(University of Pavia), Caroline Sabin(Primary Health Care), Melvyn Kahan(The Royal Free Hospital), Simon Kolstoe(University of Portsmouth), Isam Sharif(University of Edinburgh), Carol V. Robinson(Center for NanoScience)
Cited by 676
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k